Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6565095 | 0.92 | ESR1 (0.43) | ERBB2ESR1ESR2ALDH1A1CYP2C9 | |
| SCHEMBL909757 | 0.85 | ADRB2 (0.50) | ESR1ESR2HTTIDO1ALDH1A1 | |
| SCHEMBL4145904 | 0.85 | MEN1 (0.38) | ESR1ESR2HTTALDH1A1NPC1 | |
| Methane SCHEMBL7623580 | 0.83 | ADRB2 (0.48) | ESR1ESR2HTTIDO1ALDH1A1 | |
| SCHEMBL958687 | 0.82 | ALDH1A1 (0.44) | ESR1ESR2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4160843 | 0.80 | ALOX5 (0.41) | ESR1ESR2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL450037 | 0.80 | ESR1 (0.61) | ESR1ESR2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL12263781 | 0.80 | ESR1 (0.36) | ESR1ESR2ALDH1A1CYP2C9 | |
| SCHEMBL164184 | 0.80 | ALOX5 (0.41) | ESR1ESR2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL8088810 | 0.80 | LMNA (0.46) | ESR1ESR2HTTIDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | SAINT LOUIS UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| US-7135487-B2 | such as N-2-(4-Bromophenyl)propyl methanesulfonamide; sulfonamidation of the amine; glutamate receptor potentiators | ELI LILLY AND COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | ARNOLD MACKLIN B | 2006-02-09 | — | — | US | disclosed |
| EP-1528055-A2 | Sulphonamide Derivatives | Eli Lilly & Company (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-0860428-B1 | Sulphonamide derivatives | LILLY CO ELI (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040097499-A1 | Amide, carbamate, and urea derivatives | ARNOLD MACKLIN BRIAN (US) | 2004-05-20 | — | — | US | disclosed |
| US-6521605-B1 | Potentiating glutamate receptor function; treating such as psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-20020002158-A1 | Sulphonamide derivatives | ARNOLD MACKLIN B (US) | 2002-01-03 | — | — | US | disclosed |
| US-6303816-B1 | Sulphonamide derivatives | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| CN-1251523-A | Sulfonamide derivatives | LILLY CO ELI (US) | 2000-04-26 | — | — | CN | disclosed |
| WO-2000006537-A1 | N-SUBSTITUTED SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006176-A1 | AMIDOPHOSPHATE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006156-A1 | AMIDE, CARBAMATE, AND UREA DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976744-A1 | Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1998033496-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | GRIN2C, GLRA2, GLRA1 | TYR 3199/4885ERBB2 292/4885MGLL 3304/4885 |
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | P2RY14, P2RY4, P2RY13 | TYR 2817/4885ERBB2 3346/4885MGLL 1076/4885 |
| US-20020002158-A1 | Sulphonamide derivatives | GRIN2C, GRM1, GRM3 | TYR 4440/4885ERBB2 1207/4885MGLL 2001/4885 |
| US-20040097499-A1 | Amide, carbamate, and urea derivatives | GRIN2A, GLUL, GRIK5 | TYR 4015/4885ERBB2 2773/4885MGLL 2903/4885 |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | TYR 130/4885ERBB2 1480/4885MGLL 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.